Open company graph database — free web & API
Login

Kyorin Pharmaceutical Co., Ltd.

杏林製薬株式会社KYORIN Pharmaceutical Co., Ltd.Alias
Ticker
Listed market
TYO
Country
Japan
Employees (non-consolidated)
1,330
Related companies
5
§01

Basic information

BASIC
Head office
〒100-0004 Tokyo, Chiyoda-ku, Otemachi 1-3-7, Nihon Keizai Shimbun Tokyo Head Office Building
Chief executive
Yutaka Ogiwara
Capital
700,000,000  (7 100 million)
Employees (non-consolidated)
1,330 people
Employees (consolidated)
Start date
1923-01-01
End date
§02

Websites

1 DOMAINS
§03

Business

10
Manufacture and sale of pharmaceuticalsDrug discovery and developmentLicensing activitiesSalesInfection-related productsOver-the-counter drugsGeneric drugsProductionReliability assuranceHealthcare products
§04

Related companies

5 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Kyorin Pharmaceutical Holdings Co., Ltd.
Group Parent
KYORIN Remedio Co., Ltd.
Group Subsidiary
Kyorin Remedy Co., Ltd.
Group Subsidiary
Kyorin Pharmaceutical Group Factory Co., Ltd.
Group Subsidiary
NIPPON RIKA CO., LTD.
Shareholder
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

141 EVENTS

Founded in 1923 as Toyo Shinyaku Sha, the predecessor of Kyorin Pharmaceutical, and began manufacturing and selling injections.Sources

Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical Co., Ltd., was founded.Sources

In 1923 (Taisho 12), amid the aftermath of the Great Kanto Earthquake, Hiroshi Ogiwara established Toyo Shin Yakusha, the predecessor of Kyorin Pharmaceutical, in Arai-juku, Omori Ward, Tokyo, starting the company.Sources

Founded Toyo Shin-Yaku-sha, the predecessor of Kyorin Pharmaceutical Co., Ltd.Sources

Established Kyorin Chemical Research InstituteSources

Renamed Kyorin Chemical Research Institute to Kyorin Pharmaceutical Co., Ltd., and spun off the sales division to establish Kyorin Yakuhin Co., Ltd.Sources

Established Okaya FactorySources

Founded the medical journal "Doctor Salon"Sources

Established Kyorin Chemical Research Institute (later Development Technology Center)Sources

Completed the headquarters building in Kanda SurugadaiSources

Launched painkiller "Kyorin AP2"Sources

Launched oral hypoglycemic agent "Dearamin S"Sources

Established Noki FactorySources

Established Central Research InstituteSources

Merged Kyorin Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd.Sources

Established Noshiro FactorySources

Participated in capital with Nissin Pharmaceutical Co., Ltd. (renamed Nissin Kyorin Pharmaceutical Co., Ltd.)Sources

Established Research CenterSources

Launched ulcerative colitis and Crohn's disease treatment "Pentasa"Sources

Exported "Gatifloxacin" (GFLX) to Bristol-Myers Squibb (U.S.)Sources

Acquired the "Milton" business from P&GSources

Listed on the Second Section of the Tokyo Stock ExchangeSources

Designated on the First Section of the Tokyo Stock ExchangeSources

Derivation of "Gatifloxacin Eye Drops" to Alcon Inc. (USA)Sources

Established Kyorin USA, Inc. (100% owned) in the United StatesSources

Launch of the bronchial asthma treatment drug "Kipres Tablets"Sources

Established Kyorin Europe GmbH (100% owned) in GermanySources

Launch of the broad-spectrum oral antibacterial agent "Gatifloxacin" (GFLX)Sources

Acquired 100% subsidiary ActivX Biosciences, Inc. in the United StatesSources

Acquired shares of Toyo Pharma Co., Ltd. (now Kyorin Remedio Co., Ltd.) (subsidiary)Sources

Closure of Noki FactorySources

Transition to a holding company system through share exchange with Kyorin Co., Ltd.Sources

Merger of Kyorin Pharmaceutical Co., Ltd. and Nisshin Kyorin Pharmaceutical Co., Ltd.Sources

Change of trade name from Kyorin Co., Ltd. to Kyorin Pharmaceutical Holdings Co., Ltd.Sources

Acquisition of MSD Shiga Factory and founding of Kyorin Pharmaceutical Group Factory Co., Ltd.Sources

Launch of the environmental disinfectant and cleaning agent "Rubista"Sources

Relocation of headquarters to Kanda Surugadai "Ochanomizu Soramachi"Sources

Launch of the asthma treatment combination drug "Fultiform"Sources

Consolidation of the drug discovery research institute (former Central Research Institute) and development research institute (former Research Center) and establishment of Kyorin Pharmaceutical Watrasu Drug Discovery CenterSources

Launch of COPD treatment drug "Eclira Genuair"Sources

Derivation of the "FPR2 Agonist Program" to Bristol-Myers Squibb Co. (USA)Sources

Closure of Okaya FactorySources

Launch of the bronchial asthma and allergic rhinitis treatment drug "Montelukast Tablets 10mg/5mg 'KM'"Sources

Launch of allergy treatment drug "Desalex Tablets 5mg"Sources

Kyolyn Remedyo Co., Ltd. Takaoka Formulation Research Institute establishedSources

Kyorin Pharmaceutical Co., Ltd. acquires shares of Jatus Co., Ltd., and merges through absorption (entry into diagnostic business)Sources

Newly established Kyolyn Pharmaceutical Group Factory Co., Ltd. (Headquarters: Tokyo) operationalSources

Launch of overactive bladder treatment drug "Beovert Tablets 50mg"Sources

Kyolyn Pharmaceutical Group Factory Co., Ltd. and Kyolyn Medical Supply Co., Ltd. mergeSources

Launch of quinolone oral antibacterial "Lasvic Tablets 75mg"Sources

ActivX Biosciences, Inc. closedSources

Kyorin Chemical Laboratory was established.Sources

On June 16, 1931 (Showa 6), Kyorin Chemical Research Institute was established. It was designated as the founding (anniversary) day of our group, as it was the first time the name "Kyorin" was used.Sources

Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical Co., Ltd., and Kyorin Yakuhin Co., Ltd. was organized as an independent marketing division.Sources

In 1940 (Showa 15), Kyorin Chemical Research Institute was renamed Kyorin Pharmaceutical. Also, in the same year, Kyorin Yakuhin was established to handle sales.Sources

The Okaya Plant was started.Sources

In 1947 (Showa 22), as the country began to recover, the Okaya Factory was opened in Okaya City, Nagano Prefecture. It operated as the main factory until 2016 (Heisei 28).Sources

The medical journal bulletin “Doctor Salon” was started.Sources

In the 1960s, established a system for new drug research and development, and has contributed to people's health through research, development, production, and sales of new drugs to this day.Sources

Behyd, a diuretic and antihypertensive agent, was launched.Sources

Kyorin Chemical Laboratory (later Technical Center of Development) was established.Sources

In 1962 (Showa 37), Kyorin Chemical Research Institute was established in Ukima, Kita-ku, Tokyo, for new drug development. An organizational system was built.Sources

The Head Office was completed in Kanda Surugadai.Sources

KYORIN AP-2, an analgesic, was launched.Sources

Deamelin-S, an oral hypoglycemic agent, was launched.Sources

In 1965 (Showa 40), the headquarters was relocated to Kanda Surugadai, Chiyoda-ku, Tokyo. The headquarters building was completed.Sources

The Nogi Plant was opened.Sources

In 1967 (Showa 42), Noki Factory was opened, and production facilities were modernized to cope with increased production. It operated as a main factory from 1967 (Showa 42) to 2006 (Heisei 18).Sources

Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.Sources

Hespander, a plasma substitute and extracorporeal circulation flow improver, was launched.Sources

Central Research Laboratories were opened.Sources

In 1977 (Showa 52), in response to the demands of the times, the Central Research Institute was established in Noki Town, Shimotsuga District, Tochigi Prefecture, to enhance the development of original new drugs. This eventually led to the development of the long-awaited new drug, Norfloxacin (Baxdilar).Sources

Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & Co. (U.S.A.).Sources

In 1980 (Showa 55), Norfloxacin was introduced to Merck & Co. in the United States. The company also contracted with several European pharmaceutical companies, and the drug was launched in over 130 countries and regions worldwide, which demonstrated the company's drug discovery capabilities globally.Sources

Mucodyne, a mucoregulant, was launched.Sources

Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.Sources

Ketas, for bronchial asthma and cerebrovascular disorders, was launched.Sources

Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.Sources

KYORIN Pharmaceutical Co., Ltd. and Kyorin Yakuhin Co., Ltd. were merged, and the new KYORIN Pharmaceutical Co., Ltd. was founded.Sources

In 1992 (Heisei 4), to consolidate management resources and strengthen the corporate structure, Kyorin Pharmaceutical and Kyorin Yakuhin merged. The new company, Kyorin Pharmaceutical Co., Ltd., which has functions from research and development to production and sales, was launched.Sources

Megalocin (FLRX), a long-acting new quinolone agent, was launched.Sources

The Noshiro Plant was opened.Sources

In 1995 (Heisei 7), to achieve further stable production, stable supply, and productivity improvement, the company established the Noshiro Factory in Noshiro City, Akita Prefecture, and began operations as a new production base.Sources

A joint venture, Nisshin KYORIN Pharmaceutical Co., Ltd., was established with Kyorin’s capital participation.Sources

The Research Center (now the WATARASE Research Center) was founded.Sources

Pentasa, a treatment for ulcerative colitis and Crohn’s disease, was launched.Sources

Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).Sources

In 1996 (Heisei 8), aiming to strengthen the pharmaceutical business for further growth and development, the company participated in capital with Nissin Pharmaceutical Co., Ltd. and started business activities as Nissin Kyorin Pharmaceutical Co., Ltd. It merged with Kyorin Pharmaceutical in 2008 (Heisei 20).Sources

In 1996 (Heisei 8), to improve development research functions (synthesis research, safety technology, synthesis technology, formulation technology), a research center was established in Nogi Town, Tochigi Prefecture, to enhance research efficiency.Sources

In 1996 (Heisei 8), the company introduced Gatifloxacin, a new quinolone antibacterial agent, to BMS in the United States. In 2000 (Heisei 12), it introduced Gatifloxacin eye drops to Allergan in the United States.Sources

Milton, an effervescent disinfectant business, was acquired from P&G.Sources

In 1998 (Heisei 10), the company inherited the business of sterilizing disinfectants for baby bottles and nipples, Milton, from P&G Group in Japan, expanding its infectious disease-related business from treatment to prevention, and strengthening the over-the-counter drug business.Sources

Listed on the Tokyo Stock Exchange, Second Section.Sources

In April 1999 (Heisei 11), the company was listed on the Second Section of the Tokyo Stock Exchange, and was transferred to the First Section the following year, aiming to increase social standing, expand funding options, and continue investing in R&D and new business fields.Sources

Listed on the Tokyo Stock Exchange, First Section.Sources

Gatifloxacin eyedrops was licensed to Allergan (U.S.A.).Sources

A subsidiary company, Kyorin USA, Inc. (U.S.A.), was established.Sources

Kipres, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.Sources

A subsidiary company, Kyorin Europe GmbH (Germany), was established.Sources

Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.Sources

ActivX Biosciences, Inc. (U.S.A.) became a wholly owned subsidiary.Sources

In 2004 (Heisei 16), to acquire new drug discovery technology (proteomics), the company made ActivX, a biotech venture, a subsidiary to streamline and accelerate the exploration of candidate compounds. It was closed in 2023 (Reiwa 5).Sources

The stock of Toyo Pharma Co., Ltd. (present KYORIN Rimedio Co., Ltd.) was acquired, making it into a subsidiary company.Sources

In 2005 (Heisei 17), the company acquired Toyo Pharma Co., Ltd. (now Kyorin Remedio Co., Ltd.) and entered the generic drug business, working on building new businesses.Sources

The Nogi Plant was closed.Sources

The Kyorin Group shifts to a holding company structure through a share exchange with KYORIN Co., Ltd.Sources

In 2006 (Heisei 18), aiming to realize a new corporate image of a trust-based, globally-oriented drug discovery business, the company transitioned to a holding company structure and changed its name to Kyorin Corporation. In 2010 (Heisei 22), it changed its name to Kyorin Pharmaceutical Holdings, Inc., to improve recognition.Sources

Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.Sources

KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.Sources

KYORIN Co., Ltd. changed its name to KYORIN Holdings, Inc.Sources

Acquisition (conversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities Co., Ltd.Sources

RUBYSTA, a multi-purpose disinfectant cleaner, was launched.Sources

In 2012 (Heisei 24), the company acquired MSD Shiga Factory to further improve production technology and capacity, establishing a new production system.Sources

Head office moved to Ochanomizu sola city in Kanda Surugadai.Sources

Flutiform, a combination drug for asthma treatment, was launched.Sources

Establishment of the WATARASE Research Center of KYORIN Pharmaceutical Co., Ltd. through consolidation of the Drug Discovery Center and the R&D Center.Sources

Eklira Genuair, a treatment for COPD, was launched.Sources

FPR2 agonist program was licensed to Bristol-Myers Squibb Company (U.S.A.).Sources

Establishment of Watara Pharmaceutical Center.Sources

In 2015 (Heisei 27), the company consolidated its domestic research and development bases, previously dispersed across two locations, into the Watara Pharmaceutical Center on the site of the Nogi Factory in Nogi Town, Tochigi Prefecture, to enhance efficiency and collaboration.Sources

The Okaya Plant was closed.Sources

Montelukast tablets 10mg, 5mg「KM」, the leukotriene receptor antagonist and bronchial asthma treatment medicine, was launched.Sources

DESALEX Tablets 5mg, a treatment of allergic diseases, was launched.Sources

KYORIN Rimedio Co., Ltd.’s Takaoka Pharmaceutical Technology Innovation Center was established.Sources

In 2017 (Heisei 29), to strengthen the development of generic drug formulations and increase attractive in-house developed products, the company established the Takaoka Formulation Research Institute in Takaoka City, Toyama Prefecture, focusing on solid and liquid formulations.Sources

In 2017 (Heisei 29), the company acquired all shares of Jatas Inc., established to industrialize the technology developed by the National Institute of Advanced Industrial Science and Technology, and launched the ultra-fast gene quantification device GeneSoC, which has been used for COVID-19 diagnosis.Sources

New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities Co., Ltd. (head office: Tokyo), commences operations.Sources

Beova Tablets 50mg, a treatment of OAB drug, was launched.Sources

In 2018 (Heisei 30), the company absorbed and succeeded the Noshiro Factory and Kyorin Remedio's manufacturing headquarters into a new manufacturing subsidiary, and merged with the Kyorin Pharmaceutical Group Factory in Koka, Shiga Prefecture, to optimize group production and build a competitive manufacturing system that supplies high-quality products stably and at low cost.Sources

GeneSoC®, a microchannel-based genetic measurement device, was launched.Sources

KYORIN Pharmaceutical Group Facilities Co., Ltd. and KYORIN Medical Supply Co., Ltd. merge.Sources

Lasvic Tablets 75mg, an oral quinolone antibacterial agent, was launched.Sources

Lasvic Intravenous Drip Infusion Kit 150mg, an injectable new quinolone antibacterial agent, was launched.Sources

Zymso Intravesical Solution 50%, an interstitial cystitis treatment, was launched.Sources

GeneSoC® mini was launched.Sources

Lyfnua® Tablets 45mg, a selective P2X3 receptor antagonist for refractory chronic cough, was launched.Sources

ActivX Biosciences, Inc. was dissolved.Sources

In 2022 (Reiwa 4), the company reorganized from four market segments into three, listed on the Prime Market, and focused on meeting standards for performance, stock liquidity, corporate governance, and sustainability issues.Sources

KYORIN Holdings, Inc. changed its trade name to KYORIN Pharmaceutical Co., Ltd. through absorption type merger of KYORIN Pharmaceutical Co., Ltd.Sources

In 2023 (Reiwa 5), the company merged with its wholly owned subsidiary Kyorin Pharmaceutical and changed its trade name to Kyorin Pharmaceutical Co., Ltd.Sources

The Takaoka Plant was opened.Sources

§07

News

51 ARTICLES

Notice regarding changes in major shareholdersSources

On October 28, 2026, a notice regarding changes in major shareholders was announced. Please refer to the published PDF for details.

Kyorin Pharmaceutical Receives Level 2 Eruboshi CertificationSources

Kyorin Pharmaceutical received Level 2 Eruboshi Certification from the Ministry of Health, Labour and Welfare in recognition of its efforts to promote women's advancement. It meets the standards in four areas: recruitment, continued employment, working hours and other aspects of work arrangements, and diverse career paths. The company is advancing training and improving its systems, with the aim of having women make up at least 15% of managers by fiscal 2029.

Kyorin Pharmaceutical Reports Change in Specified SubsidiarySources

Kyorin Pharmaceutical Co., Ltd. published an extraordinary report on September 30, 2026. Please refer to the PDF for details.

Executive Personnel Changes at Kyorin Pharmaceutical Group FactoriesSources

Kyorin Pharmaceutical Co., Ltd. announces changes to the officers of its subsidiary Kyorin Pharmaceutical Group Factories Co., Ltd. Please refer to the PDF for details.

Notice of Executive Personnel Changes at Kyorin Rimedio Co., Ltd.Sources

Kyorin Rimedio Co., Ltd., a subsidiary of Kyorin Pharmaceutical, announced changes to its officers. Details are provided in the PDF.

Kyorin Pharmaceutical Co., Ltd. Announces Personnel ChangesSources

Kyorin Pharmaceutical Co., Ltd. announced personnel changes on September 30, 2026. Details are available in the PDF.

Notice Regarding Succession of the Generic Pharmaceuticals BusinessSources

Kyorin Pharmaceutical announced that it is holding discussions to transfer its generic pharmaceuticals business to Kyoso Kiko, a jointly funded entity planned to be established.

Kyorin Pharmaceutical Begins Selling Vibegron for Overactive Bladder in TaiwanSources

Kyorin Pharmaceutical Co., Ltd. began selling vibegron, a treatment for overactive bladder, in Taiwan through a subsidiary of Marubeni Pharmaceuticals. The medicine is a once-daily oral beta-3 adrenergic receptor agonist that improves symptoms such as urinary urgency and frequent urination.

Kyorin Pharmaceutical publishes the 2026 Integrated ReportSources

Kyorin Pharmaceutical has published the 'Integrated Report 2026' on its official website, summarizing its efforts toward sustainable growth and enhancing corporate value.

GeneSoC FluA/B Detection Kit Now AvailableSources

On September 11, 2026, Kyorin Pharmaceutical launched the GeneSoC FluA/B Detection Kit, a nucleic acid test kit for influenza viruses approved by Japan Ministry of Health, Labour and Welfare. It distinguishes influenza A and B in about 15 minutes with improved sensitivity and shorter measurement time than the previous product. It is expected to support rapid diagnosis early after symptom onset. Kyorin is advancing development and sales of GeneSoC in-vitro diagnostics for respiratory infections and other conditions.

§08

Public records

GOV
National Tax Agency basic information8010001096491
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
杏林製薬株式会社
Trade name (kana)
キョウリンセイヤク
Name in English
Corporation type
301
Address
〒100-0004 東京都千代田区大手町1丁目3番7号
Postal code
1000004
Prefecture code
13
City code
101
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2024-05-13
Change date
2024-05-07
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2316175
METI gBizINFO8010001096491
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
8010001096491
Trade name
杏林製薬株式会社
Trade name (kana)
キョウリンセイヤク
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都千代田区大手町1丁目3番7号
Postal code
1000004
Prefecture
東京都
Prefecture code
13
City or district
千代田区
City code
101
Street address
大手町1丁目3番7号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長  荻原 豊
Capital
700000000
Employees
1322
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2024-05-13
Key information
8010001096491
§09

Sources & updates

SOURCES
↑